The latest price target for Enliven Therapeutics (NASDAQ:ELVN) was reported by Baird on November 15, 2024. The analyst firm set a price target for $40.00 expecting ELVN to rise to within 12 months (a possible 63.00% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Enliven Therapeutics (NASDAQ:ELVN) was provided by Baird, and Enliven Therapeutics maintained their outperform rating.

There is no last upgrade for Enliven Therapeutics

There is no last downgrade for Enliven Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enliven Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enliven Therapeutics was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Enliven Therapeutics (ELVN) rating was a maintained with a price target of $32.00 to $40.00. The current price Enliven Therapeutics (ELVN) is trading at is $24.54, which is out of the analyst’s predicted range.